×
Home Companies Industry Politics Money Opinion LoungeMultimedia Science Education Sports TechnologyConsumerSpecialsMint on Sunday
×

Court invalidates Eli Lilly cancer drug patent

Court invalidates Eli Lilly cancer drug patent
Comment E-mail Print Share
First Published: Wed, Aug 19 2009. 12 06 AM IST
Updated: Wed, Aug 19 2009. 12 06 AM IST
San Francisco: Eli Lilly and Co.’s method of use patent for its cancer drug Gemzar was invalidated by a federal court in Michigan, the drug maker said on Tuesday.
The court ruled in a lawsuit filed by generic drug maker Sun Pharmaceutical Industries Ltd, said Mark Taylor, a spokesman for Lilly. The patent at issue deals with methods of use for Gemzar, which was set to expire in 2013.
The decision has no bearing on Lilly’s compound patent for Gemzar, a medicine for lung, breast, pancreatic and ovarian cancer with 2008 worldwide sales of $1.7 billion, Lilly said in a statement. Sun is seeking to market a generic version of the drug before Lilly’s patent expires, court documents say. Lilly claimed Sun’s generics infringe on its Gemzar patents.
Comment E-mail Print Share
First Published: Wed, Aug 19 2009. 12 06 AM IST